Financial
FY2026 revenue $401.9m (-12.3%); operating margin -6.6%; net loss $49.2m.
Cash $41.2m; debt $147.9m.
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
FY2026 revenue $401.9m (-12.3%); operating margin -6.6%; net loss $49.2m.
Cash $41.2m; debt $147.9m.
Source: official results release · Year ended 2026-06-30 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2026 | US$401.9m | -12.3% | -US$26.4m | -US$49.2m | Accuray |
Products not yet catalogued.
FY2026 revenue $401.9m (-12.3%); operating margin -6.6%; net loss $49.2m.
Cash $41.2m; debt $147.9m.
Dec 2025: Accuray announced it would cut about 15% of its global workforce in a reorganisation. Feb 2026: it disclosed errors in revenue-obligation disclosures in prior reports, filed late for its quarterly report and said amended filings would follow.
No data breaches, cyber incidents or regulator action involving Accuray found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Jun 2026: Accuray began a Class 2 FDA recall of CyberKnife systems with the Xchange collimator changer, as a collimator that fails to dock may fall from its housing if motion is started from the in-room pendant.
No notable NHS contracts, troubled implementations, disputes or terminations involving Accuray found in HSH's search of the last 24 months.
No competitors linked yet.